NeuroBo Pharmaceuticals Files 8-K

Ticker: MTVA · Form: 8-K · Filed: Jul 16, 2024 · CIK: 1638287

Neurobo Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyNeurobo Pharmaceuticals, INC. (MTVA)
Form Type8-K
Filed DateJul 16, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-statements, exhibits, sec-filing

TL;DR

NeuroBo Pharma filed a routine 8-K on July 16th, mostly financial docs.

AI Summary

On July 16, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine disclosure of company information. No specific material events or financial transactions were detailed in the provided excerpt.

Why It Matters

This filing serves as a standard disclosure for NeuroBo Pharmaceuticals, Inc., providing updates on financial statements and exhibits to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, with no indication of significant new risks or events.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for NeuroBo Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing, dated July 16, 2024, is to report financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on July 16, 2024.

What is NeuroBo Pharmaceuticals, Inc.'s state of incorporation?

NeuroBo Pharmaceuticals, Inc. is incorporated in Delaware.

What is the business address of NeuroBo Pharmaceuticals, Inc.?

The business address of NeuroBo Pharmaceuticals, Inc. is 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.

What was NeuroBo Pharmaceuticals, Inc.'s former company name?

NeuroBo Pharmaceuticals, Inc.'s former company name was Gemphire Therapeutics Inc.

Filing Stats: 673 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2024-07-16 08:30:27

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On July 16, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company") posted an updated corporate presentation to its website at https://www.neurobopharma.com/events-presentations/presentations , which the Company may use from time to time in communications or conferences. A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report"). Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company's submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Corporate Presentation, dated July 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: July 16, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing